KRAS and cancer: Constrained ethyl residue (cEt) KRAS antisense oligonucleotide AZD4785 is an antisense oligonucleotide that contains 2′-4′ ethyl residue and targets with high affinity to both wild-type and mutated KRAS mRNAs, resulting in inhibition of downstream effector pathways and antiproliferative effects in cancer cells including lung and colon cancer cell lines [102,103] (Table 3).